Peng Kuang1, Peixin Chen2,3, Lei Wang2, Wei Li2, Bin Chen2, Yu Liu2,3, Yi Xu2,3, Hao Wang2,3, Sha Zhao2, Lingyun Ye2, Feng Yu1, Hongbin Ji4, Yayi He2. 1. Department of Medical Oncology, The First Affiliated Hospital Of Nanchang University, Nanchang 330006, China. 2. Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China. 3. Tongji University, Shanghai 200433, China. 4. Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China.
Abstract
BACKGROUND: The further progression of credible expression profiling analysis of genes continues to expand our understanding of the biological characteristics in lung cancer. In this study, RNA sequencing (RNA-Seq) was used to contrast the transcriptomics profiling of small cell lung cancer (SCLC) that acquired partial response (PR) and stable disease (SD)/progressive disease (PD) after first-line chemotherapy. We aimed to illuminate the underlying mechanisms of long noncoding RNAs (lncRNAs) and microRNAs (miRNAs) in the efficacy of SCLC first-line chemotherapy. METHODS: Six male patients (mean age, 64.2 years) with SCLC were enrolled in this study. RNA-Seq was executed on the tumor tissues from 3 patients with PR outcome and 3 patients with SD or PD therapeutic effect after first-line chemotherapy. RESULTS: RNA-Seq generated 26.67×106 (±8.7×106) reads in SCLC tissues [mean (±standard deviation)]. Analysis revealed that 64 lncRNAs had higher expression and 194 had lower expression in the PR group ≥2-fold (P<0.05). Three downregulated genes in the PR group [HOXA-AS3, cancer susceptibility 9 (CASC9), and KEGG] could have a role in the insensitivity of SCLC. A total of 1,303 differential miRNAs were defined between PR and the SD or PD SCLC group, while 520 miRNAs had higher expression, and 783 had lower expression in the PR group. Two lower expressed miRNAs in the PR group (miRNA 601 and miRNA 596) might be the key genes in SCLC chemotherapy insensitivity. CONCLUSIONS: The expression of 3 gene (HOXA-AS3, CASC9, and KEGG) and 2 miRNAs (miRNA 601 and miRNA 596) were markedly decreased in SCLC patients who achieved PR. They thus might be the promising candidate genes in SCLC chemotherapy insensitivity. 2020 Annals of Translational Medicine. All rights reserved.
BACKGROUND: The further progression of credible expression profiling analysis of genes continues to expand our understanding of the biological characteristics in lung cancer. In this study, RNA sequencing (RNA-Seq) was used to contrast the transcriptomics profiling of small cell lung cancer (SCLC) that acquired partial response (PR) and stable disease (SD)/progressive disease (PD) after first-line chemotherapy. We aimed to illuminate the underlying mechanisms of long noncoding RNAs (lncRNAs) and microRNAs (miRNAs) in the efficacy of SCLC first-line chemotherapy. METHODS: Six male patients (mean age, 64.2 years) with SCLC were enrolled in this study. RNA-Seq was executed on the tumor tissues from 3 patients with PR outcome and 3 patients with SD or PD therapeutic effect after first-line chemotherapy. RESULTS: RNA-Seq generated 26.67×106 (±8.7×106) reads in SCLC tissues [mean (±standard deviation)]. Analysis revealed that 64 lncRNAs had higher expression and 194 had lower expression in the PR group ≥2-fold (P<0.05). Three downregulated genes in the PR group [HOXA-AS3, cancer susceptibility 9 (CASC9), and KEGG] could have a role in the insensitivity of SCLC. A total of 1,303 differential miRNAs were defined between PR and the SD or PD SCLC group, while 520 miRNAs had higher expression, and 783 had lower expression in the PR group. Two lower expressed miRNAs in the PR group (miRNA 601 and miRNA 596) might be the key genes in SCLC chemotherapy insensitivity. CONCLUSIONS: The expression of 3 gene (HOXA-AS3, CASC9, and KEGG) and 2 miRNAs (miRNA 601 and miRNA 596) were markedly decreased in SCLC patients who achieved PR. They thus might be the promising candidate genes in SCLC chemotherapy insensitivity. 2020 Annals of Translational Medicine. All rights reserved.
Entities:
Keywords:
Small cell lung cancer (SCLC); chemotherapy insensitivity; long noncoding RNAs (lncRNAs); microRNAs (miRNAs)
Authors: Xia Yang; Wenmei Su; Xiuyuan Chen; Qianqian Geng; Jingyi Zhai; Hu Shan; Chunfang Guo; Zhuwen Wang; Han Fu; Hui Jiang; Jules Lin; Kiran Hari Lagisetty; Jie Zhang; Yali Li; Shuanying Yang; Pierre P Massion; David G Beer; Andrew C Chang; Nithya Ramnath; Guoan Chen Journal: Transl Lung Cancer Res Date: 2019-10
Authors: Yuanyuan Wu; Liwen Hu; Yan Liang; Juan Li; Kai Wang; Xuedan Chen; Hui Meng; Xingying Guan; Kang Yang; Yun Bai Journal: Mol Cancer Date: 2017-08-30 Impact factor: 27.401
Authors: Nicholas B Larson; Shannon K McDonnell; Zachary Fogarty; Yuanhang Liu; Amy J French; Lori S Tillmans; John C Cheville; Liang Wang; Daniel J Schaid; Stephen N Thibodeau Journal: Front Genet Date: 2022-03-30 Impact factor: 4.599